Sign up United Kingdom
ReNeuron Group Plc (:RENE)

ReNeuron Group Plc (:RENE)

Share Price
56.10 p
-1.9 (-3.28 %)
Market Cap
£17.75 m
Proactive Investors - Run By Investors For Investors

ReNeuron Group Plc

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Market: LSE:RENE
52-week High/Low: 220.00p / 1.95p
Sector: Pharma & Biotech
Market Cap: 17.75M

ReNeuron Group Plc

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in ReNeuron Group Plc

ReNeuron Group Plc Timeline

“These positive long term results are highly encouraging, indicating that the CTX therapy has the potential to produce meaningful and sustained improvements in disability as well as motor function in disabled stroke patients”
In an update ahead of the company’s annual meeting it confirmed it is putting the finishing touches to data packages that will be submitted as part of its application to start a US Phase III clinical trial using its CTX cells to treat stroke victims

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use